Bessemer Group
EVLO

Bessemer Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bessemer Group’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,064
Closed -$99K – 2113
2022
Q4 		$99K Hold
3,064
– – ﹤0.01% 1042
2022
Q3 		$128K Hold
3,064
– – ﹤0.01% 981
2022
Q2 		$129K Hold
3,064
– – ﹤0.01% 975
2022
Q1 		$208K Hold
3,064
– – ﹤0.01% 817
2021
Q4 		$372K Hold
3,064
– – ﹤0.01% 708
2021
Q3 		$431K Buy
+3,064
New +$607K ﹤0.01% 603

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's EVLO Position: Q1 2023 in Review

Bessemer Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 3,064 shares — an estimated $99K sold.

Bessemer Group first reported a position in EVLO in Q3 2021 and held it in 6 quarters. The position peaked at $431K in Q3 2021. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

  • Bessemer Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bessemer Group sold 3,064 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $99K.
  • Bessemer Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • Bessemer Group's Evelo Biosciences, Inc. Common Stock position peaked at $431K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on Bessemer Group's 13F filing for Q1 2023, filed 10 May 2023.